Shift From Adalimumab Originator to Biosimilars in Denmark

被引：63

作者：

Jensen, Thomas Bo ^{[1
]}

Kim, Seoyoung C. ^{[2
]}

Jimenez-Solem, Espen ^{[1
]}

Bartels, Dorthe ^{[3
]}

Christensen, Hanne Rolighed ^{[1
]}

Andersen, Jon Traerup ^{[1
]}

机构：

[1] Copenhagen Univ Hosp Bispebjerg, Dept Clin Pharmacol, Bispebjerg Bakke 23,Entrance 20C,2nd Floor, DK-2400 Copenhagen NV, Denmark

[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA

[3] Amgros, Copenhagen, Denmark

来源：

JAMA INTERNAL MEDICINE | 2020年 / 180卷 / 06期

关键词：

D O I：

10.1001/jamainternmed.2020.0338

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：902 / 903

页数：2

共 5 条

[1] Adalimumab and the Challenges for Biosimilars [J].

Gellad, Walid F. ;

Good, Chester B. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (22) :2171-2172

[2] Obstacles to the Adoption of Biosimilars for Chronic Diseases [J].

Hakim, Aaron ;

Ross, Joseph S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (21) :2163-2164

[3] The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars [J].

Jensen, Thomas Bo ;

Bartels, Dorthe ;

Saedder, Eva Aggerholm ;

Poulsen, Birgitte Klindt ;

Andersen, Stig Ejdrup ;

Christensen, Mette Marie H. ;

Nielsen, Lars ;

Christensen, Hanne Rolighed .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (01) :35-40

[4] Top drugs and companies by sales in 2018 [J].

Urquhart, Lisa .

NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (04) :245-245

[5]

Zhai Mike Z, 2019, AMA J Ethics, V21, pE668, DOI 10.1001/amajethics.2019.668

← 1 →